drugset / Trial / NCT05606965

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

NCT05606965

Phase 2 Completed 172 enrolled ModernaTX, Inc.
RandomizedParallel-groupOpen-labelPrevention

Summary

The main purpose of the study is to evaluate the safety, reactogenicity, and the humoral immunogenicity of mRNA-1010 and comparator influenza vaccines against homologous influenza A and B strains at Day 29.

Timeline

Start
2022-11-02
Primary completion
2025-11-13
Completion
2025-11-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluad Vaccine Intramuscular
Comparator Influenza Virus Vaccine Vaccine Intramuscular
Subject Quadrivalent influenza vaccine Vaccine Intramuscular
Subject mRNA-1045 Unknown Intramuscular
Subject mRNA-1345 Messenger RNA (mRNA)

Indications